DE60328214D1 - Verfahren und zusammensetzungen in verbindung mit gen-silencing - Google Patents

Verfahren und zusammensetzungen in verbindung mit gen-silencing

Info

Publication number
DE60328214D1
DE60328214D1 DE60328214T DE60328214T DE60328214D1 DE 60328214 D1 DE60328214 D1 DE 60328214D1 DE 60328214 T DE60328214 T DE 60328214T DE 60328214 T DE60328214 T DE 60328214T DE 60328214 D1 DE60328214 D1 DE 60328214D1
Authority
DE
Germany
Prior art keywords
stranded rna
double
fragments
sequences
hsirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60328214T
Other languages
English (en)
Inventor
George Tzertzinis
George Feehery
Corinna Tuckey
Christopher Noren
Larry Mcreynolds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New England Biolabs Inc
Original Assignee
New England Biolabs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Biolabs Inc filed Critical New England Biolabs Inc
Application granted granted Critical
Publication of DE60328214D1 publication Critical patent/DE60328214D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
    • C12Y301/26003—Ribonuclease III (3.1.26.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays
DE60328214T 2002-08-12 2003-07-18 Verfahren und zusammensetzungen in verbindung mit gen-silencing Expired - Lifetime DE60328214D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40276902P 2002-08-12 2002-08-12
US40754302P 2002-08-30 2002-08-30
US46754103P 2003-05-02 2003-05-02
PCT/US2003/022540 WO2004015062A2 (en) 2002-08-12 2003-07-18 Methods and compositions relating to gene silencing

Publications (1)

Publication Number Publication Date
DE60328214D1 true DE60328214D1 (de) 2009-08-13

Family

ID=31721504

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60328214T Expired - Lifetime DE60328214D1 (de) 2002-08-12 2003-07-18 Verfahren und zusammensetzungen in verbindung mit gen-silencing

Country Status (8)

Country Link
US (2) US7700758B2 (de)
EP (1) EP1552018B1 (de)
JP (1) JP4339852B2 (de)
CN (1) CN1685063B (de)
AT (1) ATE435303T1 (de)
AU (1) AU2003256615A1 (de)
DE (1) DE60328214D1 (de)
WO (1) WO2004015062A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE508188T1 (de) 2002-02-01 2011-05-15 Life Technologies Corp Oligonukleotid-zusammensetzungen mit verbesserter wirksamkeit
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP1572902B1 (de) 2002-02-01 2014-06-11 Life Technologies Corporation HOCHWIRKSAME siRNAS ZUR REDUZIERUNG DER EXPRESSION VON ZIELGENEN
AU2003253618B2 (en) * 2002-05-31 2007-11-15 The Regents Of The University Of California Method for efficient RNA interference in mammalian cells
US20100075423A1 (en) * 2002-06-12 2010-03-25 Life Technologies Corporation Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
WO2005026322A2 (en) * 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
US20050059019A1 (en) * 2003-09-11 2005-03-17 Sven Bulow Gene-related RNAi transfection method
EP1706511A4 (de) * 2004-01-23 2010-04-07 New England Biolabs Inc Zusammensetzungen und verfahren zur erzeugung kurzer doppelsträngiger rna unter verwendung von mutierter rnase iii
WO2005095647A1 (ja) * 2004-03-31 2005-10-13 Takara Bio Inc. ｓｉＲＮＡのスクリーニング方法
RU2006138704A (ru) * 2004-05-19 2008-06-27 Вайет (Us) Модуляция производства иммуноглобулина и атопические расстройства
WO2006000410A2 (en) * 2004-06-23 2006-01-05 Bayer Bioscience N.V. Method for identifying nucleic capable of modulating a gene in a biological system
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
CN101189023B (zh) 2005-03-31 2013-01-30 通用医疗公司 监测和调制hgf/hgfr活性
ES2396440T3 (es) 2006-01-18 2013-02-21 The General Hospital Corporation Métodos de aumentar la función linfática
US10119979B2 (en) 2006-05-25 2018-11-06 Biogen Ma Inc. Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
US20100196355A1 (en) * 2007-01-29 2010-08-05 Wyeth Immunophilin Ligands and Methods for Modulating Immunophilin and Calcium Channel Activity
CA2682738A1 (en) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
US20110060135A1 (en) * 2007-11-29 2011-03-10 New England Biolabs, Inc. Selective Purification of Small RNAs from Mixtures
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
EP2894165B1 (de) 2008-11-10 2023-01-04 Alexion Pharmaceuticals, Inc. Verfahren und Zusammensetzungen zur Behandlung von komplementassoziierten Störungen
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
EP2691101A2 (de) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
DK2748192T3 (en) 2011-08-23 2019-02-25 Found Medicine Inc KIF5B-RET-FUSION MOLECULES AND APPLICATIONS THEREOF
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
WO2014022830A2 (en) 2012-08-03 2014-02-06 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
CN104870014A (zh) 2012-10-09 2015-08-26 比奥根Ma公司 联合治疗及用于治疗脱髓鞘病症的用途
CA2890207A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
EP2983804A4 (de) * 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ionenaustauschreinigung von mrna
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
ES2768648T3 (es) 2013-03-29 2020-06-23 Alexion Pharma Inc Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento
DK3019619T3 (da) 2013-07-11 2021-10-11 Modernatx Inc Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder
AU2014290044B2 (en) 2013-07-17 2020-10-29 Foundation Medicine, Inc. Methods of treating urothelial carcinomas
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
EP3169335B8 (de) 2014-07-16 2019-10-09 ModernaTX, Inc. Kreisförmige polynukleotide
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
EP3349773A4 (de) 2015-09-14 2019-05-01 Cincinnati Children's Hospital Medical Center Verfahren und zusammensetzungen zur behandlung der gaucher-krankheit durch modulation des c5a-rezeptors
US11434486B2 (en) 2015-09-17 2022-09-06 Modernatx, Inc. Polynucleotides containing a morpholino linker
CN109476731A (zh) 2016-02-29 2019-03-15 基础医药有限公司 治疗癌症的方法
BR112019000630A2 (pt) 2016-07-13 2019-07-09 Biogen Ma Inc regimes de dosagem dos antagonistas de lingo-1 e usos para tratamento de distúrbios desmielinizante
MX2020013148A (es) * 2018-06-28 2021-03-02 CureVac RNA Printer GmbH Biorreactor para la transcripcion in vitro de arn.
US20220056115A1 (en) 2018-09-17 2022-02-24 Kyoto University Administration of an anti-c5 agent for treatment of hepatic injury or failure
CN111073885A (zh) * 2019-12-31 2020-04-28 江苏耀海生物制药有限公司 一种应用于双链dna片段的纯化方法
CN112626152A (zh) * 2020-12-18 2021-04-09 深圳大学 siRNA的制备方法
CN113621686A (zh) * 2021-08-11 2021-11-09 海南微氪生物科技股份有限公司 一种适用于多种病原微生物的检测方法
WO2024045192A1 (en) * 2022-09-02 2024-03-07 Xiaomo Biotech Limited Inclusion body mediated method for double-stranded rna producing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
SK287538B6 (sk) 1998-03-20 2011-01-04 Commonwealth Scientific And Industrial Research Organisation Syntetický gén obsahujúci dispergovanú alebo cudzorodú deoxyribonukleovú molekulu, génový konštrukt obsahujúci tento syntetický gén a prípravok obsahujúci tento syntetický gén
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
CA2403397A1 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
GB2377221B (en) 2000-03-17 2004-08-18 Benitec Australia Ltd Genetic silencing
WO2001075164A2 (en) 2000-03-30 2001-10-11 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
WO2002072762A2 (en) 2001-03-08 2002-09-19 Advanced Cell Technology, Inc. Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture
US7101995B2 (en) 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
AU2003253618B2 (en) * 2002-05-31 2007-11-15 The Regents Of The University Of California Method for efficient RNA interference in mammalian cells

Also Published As

Publication number Publication date
JP4339852B2 (ja) 2009-10-07
US7700758B2 (en) 2010-04-20
AU2003256615A8 (en) 2004-02-25
WO2004015062A3 (en) 2005-02-24
US20040038278A1 (en) 2004-02-26
US20080206835A1 (en) 2008-08-28
EP1552018A2 (de) 2005-07-13
CN1685063A (zh) 2005-10-19
EP1552018B1 (de) 2009-07-01
EP1552018A4 (de) 2007-11-21
CN1685063B (zh) 2011-12-21
ATE435303T1 (de) 2009-07-15
WO2004015062A2 (en) 2004-02-19
AU2003256615A1 (en) 2004-02-25
JP2005535356A (ja) 2005-11-24

Similar Documents

Publication Publication Date Title
DE60328214D1 (de) Verfahren und zusammensetzungen in verbindung mit gen-silencing
Van Dijk et al. Library preparation methods for next-generation sequencing: tone down the bias
DE60324188D1 (de) Verfahren zur verwendung von riboprimern zur strangverdrängungsreplikation von zielsequenzen
WO2007044468A3 (en) Method to treat flavivirus infection with sirna
ATE469983T1 (de) Rolling-circle rna-amplifikation
WO2004013280A3 (en) ALLELE-SPECIFIC siRNA-MEDIATED GENE SILENCING
ATE542918T1 (de) Verfahren zur quantifizierung von mikro-rnas und kleinen interferenz-rnas
MXPA05001355A (es) Formas nuevas adicionales de moleculas de arn de interferencia.
Li et al. Identification and characterization of microRNAs in the spleen of common carp immune organ
PL1687435T3 (pl) Odporność na owady z użyciem hamowania ekspresji genów
AR039717A1 (es) Construcciones de arn de intrones cadena doble y usos de las mismas
ATE328075T1 (de) Verfahren zur hemmung der expression eine zielgens
DE60331321D1 (de) Verfahren zur wirksamen rna-interferenz in säugerzellen
DE602005022443D1 (de) Schnelle synthese von oligonukleotiden
MX2007004686A (es) Moleculas de arn de multidominio que comprenden al menos un aptamero para suministrar arn de doble hebra a organismos nocivos.
TNSN08252A1 (en) Sirna anti myosine va et depigmentation de la peau
WO2006045591A3 (en) Method and constructs for delivering double stranded rna to pest organisms
BR0309766A (pt) Promotores usp semente especìficos para expressar genes em vegetais
WO2003104470A3 (en) LET US RETURN FOR GENE TARGETING
PE20212248A1 (es) Molecula oligomerica de acido nucleico y uso de esta
WO2005042705A3 (en) Short interfering rna and micro-rna compounds and methods of designing, making and using the same
MXPA02003422A (es) Alteracion de la expresion de genes con adnss producido in vivo.
ATE420975T1 (de) Methode zur linearen nicht-selektiven amplifikation von nukleinsäuren
ATE491035T1 (de) Verfahren zur abtrennung selektionierbarer markergensequenzen
Fukuda et al. Improved design of hammerhead ribozyme for selective digestion of target RNA through recognition of site-specific adenosine-to-inosine RNA editing

Legal Events

Date Code Title Description
8364 No opposition during term of opposition